VC-backed Inotek Pharmaceuticals unveils IPO

Lexington, Massachusetts-based Inotek Pharmaceuticals Corp, a biopharmaceutical firm focused on developing treatments for glaucoma, has debuted its IPO after pricing its over 6.6 million shares at $6 per share. The stock began trading Wednesday on the NASDAQ under the ticker symbol "ITEK." Cowen and Company LLC and Piper Jaffray & Co are serving as the lead underwriters. Inoteck's backers include Devon Park Bioventures, Rho Ventures, Care Capital, Medimmune Ventures, Pitango Venture Capital and Horizon Technology Finance Corp.

North AmericaUSBriefs